• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Massachusetts General Hospital to Co-Develop VR Digital Therapeutic for Stem Cell Patients

by Jasmine Pennic 03/02/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Massachusetts General Hospital to Co-Develop VR Digital Therapeutic for Stem Cell Patients

What You Should Know:

– Massachusetts General Hospital (“MGH”) announced a research agreement with Rocket VR Health, an emerging digital therapeutics company developing clinically validated virtual reality therapies that enhance the quality of life of cancer patients, their families and their caregivers.

– The research will study the effects of daily Virtual Reality Therapy’s effect on patients during their entire hospital stay.

Partnership Details

The average hospital length of stay for patients with hematologic malignancies who undergo HCT is approximately 28 days. During this intense hospitalization period, patients can’t leave their rooms as their immune system is weakened while their bone marrow is re-generated. As a result, with no contact with the outside world, these patients endure significant short-term and long-term distress that affects their quality of life (QOL) and their physical and psychological well-being – both in the near term and long-term.

As part of the agreement, Rocket VR Health will leverage its virtual reality therapy platform to co-develop a VR digital therapeutic solution based on population-specific well-researched care interventions created by Massachusetts General Hospital. This Digital Therapeutic Solution is intended to help with distress management in blood cancer patients undergoing hematopoietic stem cell transplantation (HCT) in an in-clinic setting. HCT can be used to treat certain types of cancer, such as leukemia, myeloma, and lymphoma, and other blood and immune system diseases that affect the bone marrow.

The treatment being developed consists of 7 modules integrating psychoeducation, therapy and relaxation exercises offered over a 4-week period in beautiful virtual reality (VR) environments designed to be self-administered by patients while they are in their transplant rooms after an initial assistance and on-boarding help from a nurse or other healthcare professional. The immersive environments, imagery, sounds and music included in the Rocket VR Health platform allow patients to access the outside world virtually while being confined to their hospital room.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: cancer, Caregivers, Digital Therapeutics, Virtual Reality

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Research Report

2026 Best in KLAS Awards: The Full List of Software & Services Winners

Most-Read

The "Platform" Squeeze: Epic Releases Native AI Charting, Putting Venture-Backed Scribes on Notice

The “Platform” Squeeze: Epic Releases Native AI Charting, Putting Venture-Backed Scribes on Notice

Analysis: Oracle Cerner’s Plans for a National EHR

Oracle May Cut 30k Jobs and Sell Cerner to Fund $156B OpenAI Deal

The $1.9B Exit: Why CommonSpirit is Insourcing Revenue Cycle and Tenet is Betting Big on Conifer AI

The $1.9B Exit: Why CommonSpirit is Insourcing Revenue Cycle and Tenet is Betting Big on Conifer AI

KLAS 2026 Rankings: Aledade and Guidehealth Named Top VBC Enablement Firms

KLAS 2026 Rankings: Aledade and Guidehealth Named Top VBC Enablement Firms

Beyond the Hype: New KLAS Data Validates the Financial and Clinical ROI of Ambient AI

Beyond the Hype: New KLAS Data Validates the Financial and Clinical ROI of Ambient AI

Anthropic Debuts ‘Claude for Healthcare’ and Opus 4.5 to Engineer the Future of Life Sciences

Anthropic Debuts ‘Claude for Healthcare’ and Opus 4.5 to Engineer the Future of Life Sciences

OpenAI Debuts ChatGPT Health: A ‘Digital Front Door’ That Connects Medical Records to Agentic AI

OpenAI Debuts ChatGPT Health: A ‘Digital Front Door’ That Connects Medical Records to Agentic AI

From Genes to Hackers: The Hidden Cybersecurity Risks in Life Sciences

From Genes to Hackers: The Hidden Cybersecurity Risks in Life Sciences

Utah Becomes First State to Approve AI System for Prescription Renewals

Utah Becomes First State to Approve AI System for Prescription Renewals

NYC Health + Hospitals to Acquire Maimonides in $2.2B Safety Net Overhaul

NYC Health + Hospitals to Acquire Maimonides in $2.2B Safety Net Overhaul

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |